IOL Chemicals IOL Chemicals

X

Find the latest Drugs in Development and Pipeline Prospector News of Recipharm AB.

  • Webinars & Exhibitions

PharmaCompass
left grey arrow
right gray arrow

Details:

Product characterization is an important next step for RSBT-001 before filing an Investigational New Drug (IND) application with the FDA for the treatment of chronic obstructive pulmonary disease (COPD).


Lead Product(s): RSBT-001

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RSBT-001

Highest Development Status: PreclinicalProduct Type: Small molecule

Recipient: RS BioTherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership November 14, 2022

Recipharm Company Banner

ASPEN 2024

Not Confirmed

envelop Contact Supplier

Details:

Recipharm is developing and commercializing inhalation technologies and products in support of the development and advancement of Transpire Bio’s TRB-1 and TRB-2 respiratory products.


Lead Product(s): TRB-1

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TRB-1

Highest Development Status: PreclinicalProduct Type: Small molecule

Recipient: Transpire Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 14, 2022

Recipharm Company Banner

ASPEN 2024

Not Confirmed

envelop Contact Supplier

Details:

The acquisition of Recipharm, to provide innovative drug developers in the Biologics market with differentiated contract development and manufacturing services for ATMPs and builds on the capabilities acquired through GenIbet transaction and acquisition of Vibalogics.


Lead Product(s): Microbiome Therapeutic

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Large molecule

Recipient: Arranta Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition February 18, 2022

Recipharm Company Banner

ASPEN 2024

Not Confirmed

envelop Contact Supplier

Details:

Recipharm has reserved capacity to support the anticipated demand for the mRNA-1273 vaccine and is already in the process of recruiting additional staff and making certain investments to enable technology transfer and scale-up to commence imminently.


Lead Product(s): mRNA-1273

Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1273

Highest Development Status: Phase IIIProduct Type: Vaccine

Partner/Sponsor/Collaborator: Moderna Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement November 24, 2020

Recipharm Company Banner

ASPEN 2024

Not Confirmed

envelop Contact Supplier

Details:

The study indicates that patients taking Erdosteine after hospital discharge benefit significant improvements in health-related quality of life parameters (HRQoL) and dyspnoea. This study is one of the first to report HRQoL details in patients with COVID-19.


Lead Product(s): Erdosteine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 14, 2020

Recipharm Company Banner

ASPEN 2024

Not Confirmed

envelop Contact Supplier

Details:

Arcturus has secured manufacturing slots with Recipharm to support the manufacture of ARCT-021, Arcturus’ COVID-19 vaccine candidate that is in an ongoing phase 1/2 clinical trial.


Lead Product(s): ARCT-021

Therapeutic Area: Infections and Infectious Diseases Product Name: LUNAR-COV19

Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine

Partner/Sponsor/Collaborator: Arcturus Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement October 06, 2020

Recipharm Company Banner

ASPEN 2024

Not Confirmed

envelop Contact Supplier

Details:

The new agreement provides both companies with a long-term partnership that will ensure continued supply for patients across the globe. Opicapone (Ongentys) is approved in Europe, USA, South Korea, Taiwan, Australia and Japan.


Lead Product(s): Opicapone

Therapeutic Area: Neurology Product Name: Ongentys

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Bial

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement October 01, 2020

Recipharm Company Banner

ASPEN 2024

Not Confirmed

envelop Contact Supplier

Details:

Under the contract, Vibalogics will produce multiple batches of the vaccine candidate at its facility in Cuxhaven, Germany, expected to yield thousands of vaccine doses.


Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Vaccine

Partner/Sponsor/Collaborator: Johnson & Johnson

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 19, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY